Bayer and Iambic collaborate to advance drug discovery with AI

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

Iambic to Participate in March Investor Conferences

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery

San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

Enchant whitepaper: Breaking the data wall between lab and clinic

Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery

Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

The Bio Report: A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery

BIOS Builders #23 with Tom Miller

Ascenta Investor Day: A Conversation with David M. Rubenstein and Tom Miller

Tom Miller Presents at the NVIDIA Spring GTC23 Event

Caltech Heritage Project: A profile on Tom Miller, CEO of Iambic

Tom Miller Presents at PBSS Symposium 2021